Quest Diagnostics (DGX) Raises Quarterly Dividend 15.2% to $0.38; 2.2% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Quest Diagnostics (DGX) Tops Q4 EPS by 4c; Guides Above the Street
January 29, 2015 7:18 AM ESTQuest Diagnostics (NYSE: DGX) reported Q4 EPS of $1.08, $0.04 better than the analyst estimate of $1.04. Revenue for the quarter came in at $1.9 billion versus the consensus estimate of $1.85 billion.
Quest Diagnostics sees FY2015 EPS of $4.70-$4.85, versus the consensus of $4.43. Revenues to increase approximately 2% to... More
RedHill Biopharma (RDHL) Completes pre-IND Meeting for RHB-104 Phase III; Offers Progress Update
January 29, 2015 7:14 AM ESTRedHill Biopharma (Nasdaq: RDHL) provided an update on the progress with the ongoing RHB-104 Phase III development program for the treatment of Crohn's disease. The Company, together with Quest Diagnostics (NYSE: DGX), recently concluded a pre-submission meeting with the FDA regarding the development path of a commercial companion diagnostic test for the detection of Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn's disease patients. Following the constructive FDA meeting, RedHill intends to initiate a study of approximately 40 Crohn's disease patients to assess the clinical utility of the companion... More
